This is achieved by decreasing the expression of PD-L1 in the tumor microenvironment and downregulating the proportion of PD-1/TIM-3-expressing T cells, regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. This evidence concerns the gene CD274 and neoplasm.